FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company, today announced...
Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL”...
Transaction expected to approximately triple NEXGEL’s annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified...
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of...
FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that on April...
Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio ...
Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications. Three pipeline...
Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified...
Transaction expected to generate up to $35 million in upfront and milestone payments Celularity retains exclusive manufacturing rights, creating continued biomaterials revenue and margin opportunity ...
FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2...